School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

FILANA THERAPEUTICS, INC. FLNA

Healthcare · Biotechnology

$0.82last close 2026-10-09 · market cap $39.46M · delayed data

Trailing returns

1M+1.23%
3M-31.09%
6M-52.33%
1Y-80.43%
5Y-98.41%

Basis: Adjusted daily closes.

What it does

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of…

Open FLNA in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies